<!-- This content is only licensed for consumption by authorized users affiliated with PubMed Central. Usage by any individual not directly associated with PubMed Central is prohibited. -->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" id="a402758408" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cryst Growth Des</journal-id><journal-id journal-id-type="iso-abbrev">Cryst Growth Des</journal-id><journal-id journal-id-type="publisher-id">cg</journal-id><journal-id journal-id-type="coden">cgdefu</journal-id><journal-title-group><journal-title>Crystal Growth &#x00026; Design</journal-title></journal-title-group><issn pub-type="ppub">1528-7483</issn><issn pub-type="epub">1528-7505</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher><self-uri>pubs.acs.org/crystal</self-uri></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12100653</article-id><article-id pub-id-type="doi">10.1021/acs.cgd.5c00184</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Discovery of Cilnidipine
Cocrystals with Enhanced
Dissolution by the Use of Computational Tools and Semiautomatic High-Throughput
Screening</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e23-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6369236</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-9430-7030</contrib-id><name><surname>Guidetti</surname><given-names>Matteo</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">770719</contrib-id><name><surname>Hilfiker</surname><given-names>Rolf</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2024897</contrib-id><name><surname>De Paul</surname><given-names>Susan M.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1691114</contrib-id><name><surname>Bauer-Brandl</surname><given-names>Annette</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">853399</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2879-9577</contrib-id><name><surname>Blatter</surname><given-names>Fritz</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1173182</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2963-2645</contrib-id><name><surname>Kuentz</surname><given-names>Martin</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff3" ref-type="aff"/></contrib><aff id="aff1">
<label>&#x02020;</label>
<institution content-type="dept">Solid-State
Development Department</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">30275</institution-id><institution>Solvias AG</institution></institution-wrap>, <addr-line>R&#x000f6;merpark 2</addr-line>, <postal-code>CH- 4303</postal-code>
<city>Kaiseraugst</city>, <country country="CH">Switzerland</country>
</aff><aff id="aff2">
<label>&#x02021;</label>
<institution content-type="dept">Department
of Physics, Chemistry and Pharmacy</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">6174</institution-id><institution>University
of Southern Denmark</institution></institution-wrap>, <addr-line>Campusvej 55</addr-line>, <postal-code>5230</postal-code>
<city>Odense</city>, <country country="DK">Denmark</country>
</aff><aff id="aff3">
<label>&#x000a7;</label>
<institution content-type="dept">Institute
of Pharma Technology</institution>, <institution>University of Applied
Sciences and Arts Northwestern Switzerland</institution>, <postal-code>CH- 4132</postal-code>
<city>Muttenz</city>, <country country="CH">Switzerland</country>
</aff></contrib-group><author-notes><corresp id="cor1">
<label>*</label>Email: <email>martin.kuentz@fhnw.ch</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>21</day><month>5</month><year>2025</year></pub-date><volume>25</volume><issue>10</issue><fpage>3374</fpage><lpage>3385</lpage><history>
<date date-type="received"><day>13</day><month>2</month><year>2025</year></date>
<date date-type="accepted"><day>22</day><month>4</month><year>2025</year></date>
<date date-type="rev-recd"><day>11</day><month>4</month><year>2025</year></date>
<date date-type="online"><day>29</day><month>4</month><year>2025</year></date>
</history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" content-type="AuthorChoicev2" start_date="2025-04-29"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-04-29">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><abstract><p>Cocrystals are an
attractive option for overcoming drug
limitations,
such as a low dissolution rate and absorption of poorly water-soluble
compounds. Nevertheless, the discovery of new cocrystals remains a
trial-and-error approach in which hundreds of coformers and several
experimental methods are often tested. To streamline the cocrystal
screening, computational methods can be used to select the coformers
most likely to form a cocrystal, while high-throughput screening (HTS)
approaches can rapidly screen them experimentally. In this manuscript,
a new cocrystal of the extremely poorly soluble drug cilnidipine (solubility
&#x02248;30 ng/mL, 0.06 &#x003bc;M) was successfully discovered by applying
HTS approaches. Only one cocrystal resulted from the screening with
a total of 52 coformers, whereby the computational approach molecular
complementarity successfully ranked this coformer (<italic toggle="yes">p</italic>-toluenesulfonamide) at the third position of the screening list.
Dissolution studies conducted on the cocrystal in blank FaSSIF (fasted-state
simulated intestinal fluid) and FaSSIF pH 6.5 revealed enhanced drug
dissolution with a maximum achieved supersaturation equal to seven
times the solubility of the crystalline drug. Dissolution rates of
drug and coformer were compared for better mechanistic understanding
of the cocrystal dissolution&#x02013;supersaturation&#x02013;precipitation
behavior. The case of cilnidipine with a rare occurrence of cocrystals
emphasized the importance of using joint computational and HTS approaches
to enable successful cocrystal identification for pharmaceutical development.</p></abstract><abstract abstract-type="graphical"><graphic xlink:href="cg5c00184_0011.jpg" position="float"/></abstract><abstract abstract-type="toc-graphic"><graphic xlink:href="cg5c00184_0009.jpg" id="tgr1" position="float"/></abstract><funding-group><award-group id="fnd-1"><funding-source>
<institution-wrap><institution>H2020 Marie Sklodowska-Curie Actions</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100010665</institution-id></institution-wrap>
</funding-source><award-id>955756</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>cg5c00184</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>cg5c00184</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>3845548fd1798a7958afa0bf1b7347b34634764e44572da30c50d10809c91ce9</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Most active pharmaceutical ingredients
(APIs) in the development
pipeline display low solubility in water and belong to Class II of
the Biopharmaceutics Classification System (BCS).<xref rid="ref1" ref-type="bibr"/> Poor aqueous solubility can lead to higher doses and erratic
behavior when a drug is administered orally. A common strategy to
address this issue is the formation of multicomponent solid forms,
such as salts, cocrystals, and coamorphous systems.<xref rid="ref2" ref-type="bibr"/>
</p><p>In particular, pharmaceutical cocrystals are developed
by combining
a poorly water-soluble API with a hydrophilic small organic molecule
called a coformer. The two components are present in a defined stoichiometric
ratio in a crystalline phase and, typically, are held together by
nonionic interactions.<xref rid="ref3" ref-type="bibr"/> The dissociation
of the components in solution may generate supersaturation of the
API, which is a driving force for molecular absorption and will eventually
lead to the precipitation of the parent drug. Co-crystal dissolution,
supersaturation, and precipitation (DSP) behavior can be modulated
by changes in pH and surfactant concentration in the dissolution media<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>,<xref rid="ref5" ref-type="bibr"/>
</named-content> or by addition of excess coformer.<xref rid="ref6" ref-type="bibr"/>
</p><p>Despite the variety of experimental screening methods reported&#x0e5f8;including
reaction crystallization,<xref rid="ref7" ref-type="bibr"/> mechanochemical,<xref rid="ref8" ref-type="bibr"/> and thermal<xref rid="ref9" ref-type="bibr"/> methods&#x0e5f8;the
discovery of cocrystals remains a tedious, trial-and-error approach.
For this reason, in the last two decades, computational (or theoretical)
screening methods have been developed to predict the formation of
new cocrystals.<xref rid="ref10" ref-type="bibr"/> The aim of these computational
tools is to reduce the number of experiments by selecting the coformers
most likely to yield a cocrystal.</p><p>To describe cocrystal formation,
two contributions must be taken
into account: the miscibility between the API and coformer represented
by the short-range intermolecular interactions and the long-range
crystal order affected by the molecular packing.<xref rid="ref11" ref-type="bibr"/> Crystal structure prediction (CSP) considers both contributions
to cocrystallization and has demonstrated accurate prediction of cocrystals
for small organic molecules.<xref rid="ref12" ref-type="bibr"/> However,
the CSP is based on time-demanding quantum chemical calculations;
at the current status, increasing the number of investigated coformers
or the molecular size of the API would lead to long-lasting and computationally
expensive virtual screening. Therefore, other computational methods,
which offer faster screening time and are less resource-intensive,
are often employed, despite their reduced accuracy.</p><p>Two of these
methods are represented by Molecular Complementarity
(MC) and COSMOquick. MC was developed by F&#x000e1;bi&#x000e1;n based
on the findings that cocrystallizing molecules tend to have similar
shape and polarity.<xref rid="ref13" ref-type="bibr"/> The approach can
be used to rank coformers according to the value of a complementarity
score, which describes the similarity of the coformer to the API.<xref rid="ref14" ref-type="bibr"/> Using a different approach, the COSMOquick software
ranks coformer candidates according to their miscibility with the
API in a supercooled liquid phase, considering hydrogen bonding, van
der Waals forces, and electrostatic interactions.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>&#x02212;<xref rid="ref16" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref17" ref-type="bibr"/>
</named-content> The method
is based on the COSMO-RS theory (COnductor-like Screening MOdel for
Real Solvents), a thermodynamic liquid-phase theory that combines
density functional theory (DFT) calculations and statistical thermodynamics
to accurately predict solvation properties of molecules (e.g., solubility).<named-content content-type="bibref-group">
<xref rid="ref18" ref-type="bibr"/>,<xref rid="ref19" ref-type="bibr"/>
</named-content> The method is quick in the sense that a fragment-based approach
makes use of a large data set of previous DFT calculations, thereby
avoiding lengthy computations.<xref rid="ref15" ref-type="bibr"/> For cocrystal
screening, the COSMOquick approach has been retrospectively validated
on a set of 318 coformer&#x02013;API pairs.<xref rid="ref17" ref-type="bibr"/> MC and COSMOquick have been recently employed for the prediction
of cocrystals of API molecules of different sizes.<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>,<xref rid="ref21" ref-type="bibr"/>
</named-content>
</p><p>To further streamline cocrystal screening, high-throughput
experimental
approaches can be employed for the simultaneous and parallel testing
of several coformers. Recently, we successfully identified new cocrystals
of posaconazole by employing a combined virtual and experimental high-throughput
screening (HTS).<xref rid="ref22" ref-type="bibr"/> Good prediction performances
were obtained by the ranking of coformers through the use of the complementarity
score. While this prior art shows the promise of these screening methods,
there is a need to learn about the performance of a joint approach
of using computation and an experimental screening method from prospective
case studies in cocrystal research.</p><p>In this manuscript, the
applicability of the combined approach
to discover new cocrystals is tested on the drug cilnidipine (CILP, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>). CILP is a dihydropyridine
calcium-channel blocker (reported p<italic toggle="yes">K</italic>
<sub>a</sub> =
11.4)<xref rid="ref23" ref-type="bibr"/> used in the treatment of hypertension.
This drug belongs to BCS class II as demonstrated by its extremely
low solubility in water (30&#x02013;60 ng/mL, BCS class II)<xref rid="ref24" ref-type="bibr"/> and very high lipophilicity (logP &#x02248;5.5)<sup>23</sup>. CILP was chosen as a model compound because, despite coamorphous
systems<xref rid="ref25" ref-type="bibr"/> and amorphous solid dispersions<named-content content-type="bibref-group">
<xref rid="ref26" ref-type="bibr"/>,<xref rid="ref27" ref-type="bibr"/>
</named-content> being reported, no multicomponent crystal forms of the API have
been previously discovered. This study aims (1) to find new cocrystals
of cilnidipine by using a combined computational and experimental
high-throughput screening approach, (2) to evaluate the prediction
performance of two computational tools, and (3) to assess the dissolution
behavior of the newly discovered cocrystal.</p><fig position="float" id="fig1" fig-type="figure"><label>1</label><caption><p>Chemical structures of
cilnidipine (CILP) and <italic toggle="yes">p</italic>-toluenesulfonamide (TSA).</p></caption><graphic xlink:href="cg5c00184_0001" id="gr1" position="float"/></fig></sec><sec id="sec2"><title>Materials and Methods</title><sec id="sec2.1"><title>Materials</title><p>Cilnidipine (CILP) was purchased from abcr
GmbH (Karlsruhe, Germany) and used without further purification. Co-crystal
formers were purchased from Merck &#x00026; Cie (Buchs, Switzerland) and
used as received. A list with all the cocrystal formers used in the
study is reported in the Supporting Information (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). Sodium hydroxide, sodium dihydrogen phosphate dihydrate,
sodium chloride, and acetonitrile (analytical grade) were purchased
from Sigma-Aldrich (St. Louis, USA). Trifluoroacetic acid (TFA) was
purchased from VWR International (S&#x000f8;borg, Denmark), and Fasted
State Simulated Intestinal Fluid (FaSSIF) powder was purchased from <ext-link xlink:href="http://biorelevant.com" ext-link-type="uri">biorelevant.com</ext-link> (London,
UK).</p></sec><sec id="sec2.2"><title>Medium Preparations</title><p>Blank Fasted-State Simulated Intestinal
Fluid (FaSSIF) pH 6.5 (which is a plain phosphate buffer) was prepared
by dissolving 0.42 g of sodium hydroxide, 6.18 g of sodium chloride,
and 4.47 g of sodium dihydrogen phosphate dihydrate in 950 mL of demineralized
water. The pH was adjusted to pH 6.5 with a few drops of a 1 M NaOH
solution, and the volume was filled up to 1 L with demineralized water.
Standard FaSSIF pH 6.5 was obtained by dissolving 672 mg of FaSSIF
powder in 300 mL of blank FaSSIF. The standard FaSSIF differs from
the blank version in its inclusion of the biorelevant surfactant lecithin
(0.75 mM) and the bile salt sodium taurocholate (3 mM).</p></sec><sec id="sec2.3"><title>Methods</title><sec id="sec2.3.1"><title>Cocrystal
Former Selection</title><p>The coformers for the cocrystal
screening with cilnidipine were selected after performing a computational
screening using COSMOquick on a list of 140 compounds. The top-ranked
52 coformers available in the laboratory were employed in subsequent
experimental screening. The 52 coformers were also ranked according
to the molecular complementarity (MC) method to compare the prediction
abilities of the two computational tools. Details on the two methods
are reported in the &#x0201c;<xref rid="sec2.15" ref-type="sec">Computational Cocrystal
Screening</xref>&#x0201d; section.</p></sec><sec id="sec2.3.2"><title>High-Throughput Screening</title><p>A first &#x0201c;manual&#x0201d;
high-throughput screening (HTS-1) for cocrystals was conducted in
a 96-well quartz-bottomed microtiter plate with 31 coformers (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). The screening experiments
were performed in triplicate; each trial comprised one control well
(free drug) and 31 test wells (one for each CILP-coformer pair). First,
0.05 M solutions of cilnidipine and coformers were prepared in different
solvents (acetone, methanol, and THF). Then, volumes of solutions
containing equimolar amounts of coformer and API were added to the
wells according to the plate layout reported in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Figure S1</ext-link>. The high-throughput method involved two steps:<list list-type="bullet"><list-item><p>An evaporation step under nitrogen
flow;</p></list-item><list-item><p>A slurry equilibration step conducted
by resuspending
the solid residues in three different solvents (TBME, methanol, and
ethanol) and shaking for several days at 25 &#x000b0;C.</p></list-item></list>
</p><table-wrap position="float" id="tbl1"><label>1</label><caption><title>Summary of Experimental Conditions
Employed in the Two High-Throughput Screenings</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th align="center">&#x000a0;</th><th align="center">HTS 1</th><th align="center">HTS 2</th></tr></thead><tbody><tr><td align="left">no. coformers</td><td align="left">31</td><td align="left">23</td></tr><tr><td align="left">amount API (mg
per well)</td><td align="left">2.5</td><td align="left">2.5</td></tr><tr><td align="left">evaporation solvents</td><td align="left">THF, MeOH, acetone</td><td align="left">ETOH</td></tr><tr><td align="left">slurry&#x000a0;1&#x0e5f8;solvent</td><td align="left">ETOH</td><td align="left">ETOH</td></tr><tr><td align="left">slurry&#x000a0;2&#x0e5f8;solvent</td><td align="left">TBME</td><td align="left">acetonitrile</td></tr><tr><td align="left">slurry&#x000a0;3&#x0e5f8;solvent</td><td align="left">MeOH</td><td align="left">MeOH&#x02013;H<sub>2</sub>O</td></tr><tr><td align="left">detection Type</td><td align="left">Raman microscopy</td><td align="left">PXRD</td></tr></tbody></table></table-wrap><p>At the end of each step, the solid
residues were dried
under a
nitrogen flow and analyzed by Raman microscopy (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>). The plate was covered with aluminum foil during
the HTS with the exception of during the Raman microscopy measurements.</p><p>A second &#x0201c;semi-automatic&#x0201d; high-throughput screening
(HTS-2) was conducted with 23 coformers (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>) in a modified 96-well glass plate, in which the base of
the wells can be lifted to the top of the plate thanks to the presence
of metal pistons. The screening experiments were performed in quadruplicate.
First, 0.05 M solutions of cilnidipine and coformers were prepared
in ethanol and loaded onto the Crissy 2002 automated liquid handling
platform (Zinsser Analytics, Eschborn, Germany). The screening followed
a similar procedure to that of HTS-1 with the robotic system managing
all the operations (solvent dispensing, evaporation, and agitation
for slurry equilibration). The plate was covered with a pierceable
lid during the entire crystallization step to avoid light exposure.
Upon completion of the experiments and evaporation of the solvents,
the plate was covered with a layer of Kapton foil and the base of
the wells was gently raised to press the solid material against the
bottom of the Kapton foil. The solid residues were subsequently analyzed
by PXRD.</p><p>Potential leads, identified by the presence of new
features in
the Raman spectra or new reflections in the diffraction patterns compared
to the reactants, were further investigated by liquid-assisted grinding
(LAG) and reaction crystallization<xref rid="ref7" ref-type="bibr"/> experiments.</p></sec></sec><sec id="sec2.4"><title>Liquid-Assisted Grinding and Reaction Crystallization Experiments</title><p>Liquid-assisted grinding (LAG): CILP (75 mg, 0.152 mmol) and an
equimolar amount of coformer were placed into a 3 mL agate milling
jar together with 30&#x02013;50 &#x003bc;L of the solvent (usually ethanol)
and two agate milling balls 5 mm in diameter. The mixture was agitated
in a Retsch MM200 ball mill (Retsch, Haan, Germany) at the operating
frequency of 30 Hz for two 15 min intervals with a cool-down period
of 5 min between them. The resultant solid products were tested by
FT-Raman spectroscopy.</p><p>Reaction crystallization: A solvent in
which CILP and the coformer have a similar solubility (at least the
same order of magnitude, if possible) was chosen for each experiment
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). CILP (approximately 100 mg)
was added either to an almost saturated coformer solution or to an
equimolar coformer solution and magnetically stirred for 2 days at
RT. Each vial was covered with aluminum foil to prevent light exposure.
The suspension was filter-centrifuged through a 0.2 &#x003bc;m PTFE
membrane, and the solid phase was characterized by FT-Raman spectroscopy
or powder X-ray diffraction (PXRD). In this manuscript, the term &#x0201c;slurry
equilibration&#x0201d; refers to HTS experiments, while &#x0201c;reaction
crystallization&#x0201d; refers to the reproduced experiment at a larger
scale. Despite the difference in scale, both terms describe similar
methods.</p></sec><sec id="sec2.5"><title>Cilnidipine&#x0e5f8;<italic toggle="yes">p</italic>-Toluenesulfonamide Cocrystal
1:1 (CILP-TSA)</title><p>The CILP-TSA cocrystal was scaled up using
the reaction crystallization method.<xref rid="ref7" ref-type="bibr"/> CILP
(150 mg, 0.31 mmol) was added to an almost saturated solution (4 mL)
of TSA (500 mg, 2.92 mmol, 9.4 equiv) in ethanol and magnetically
stirred at RT for 2 days. After a few seconds of stirring, the solution
turned yellow. The vial was covered with aluminum foil to prevent
light exposure of the suspension. A bright yellow powder was isolated
after filtration.</p></sec><sec id="sec2.6"><title>Solubility Determination</title><p>The equilibrium
solubility
of crystalline CILP was measured in blank FaSSIF at pH 6.5 and in
standard FaSSIF at pH 6.5, in the absence and presence of TSA (200
&#x003bc;g/mL, 1.17 mM). Excess crystalline CILP (20 mg, 0.041 mmol)
and 10 mL of media were added into screw-cap glass vials. The system
was stirred using a magnetic stirring bar at 37 &#x000b0;C. The solubility
tests were performed in triplicate. After 24 h, 1 mL of suspension
was removed and filtered through Anotop syringe filters (Whatman,
Maidstone, UK) with a pore size of 0.2 &#x003bc;m and a 25 mm diameter.
The filter was presaturated with 4 mL of a saturated solution of CILP
in blank FaSSIF. After discarding the first eight drops, the remaining
filtrate was diluted with the mobile phase and quantified by UHPLC-UV.</p></sec><sec id="sec2.7"><title>Dissolution Studies</title><p>Cocrystal dissolution studies were
conducted in triplicate in blank FaSSIF (pH 6.5) and FaSSIF pH 6.5.
A total of 10.8 mg of the cocrystal (containing 8 mg of CILP and 2.8
mg of TSA; 0.016 mmol) was added to 80 mL of dissolution media in
a beaker (height 70 mm, diameter 50 mm). The system was stirred using
a magnetic stirrer (1.5 cm, 300 rpm), and the temperature was maintained
at 25 &#x000b0;C. Aliquots of 1.0 mL were taken with a syringe at selected
time points of up to 24 h and filtered through presaturated Anotop
syringe filters (Whatman, Maidstone, UK) with a pore size of 0.2 &#x003bc;m
and a 25 mm diameter (the first eight drops were discarded). The filtrate
was diluted with mobile phase and analyzed by UHPLC-UV. The final
solid residue was recovered through vacuum filtration and was characterized
by PXRD. The percentage of cocrystal dissolved was calculated by taking
the ratio of the amount of coformer dissolved to the amount of coformer
initially added (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S6</ext-link>).</p></sec><sec id="sec2.8"><title>Raman Microscopy</title><p>The high-throughput plate from HTS-1
was analyzed using a Horiba XploRA PLUS confocal Raman microscope
from Horiba Jobin Yvon SAS (Villeneuve d&#x02019;Ascq, France) equipped
with a 100 mW 785 nm diode laser for excitation and a Syncerity OE
CCD detector. Measurements were carried out with a long working distance
20&#x000d7; objective, a 50% or 100% laser power, a 1200 lines/mm grating,
a 100 &#x003bc;m slit, with 2 accumulations of 30 s each, and a measurement
range of 200&#x02013;2000 cm<sup>&#x02013;1</sup>.</p></sec><sec id="sec2.9"><title>FT-Raman Spectroscopy</title><p>FT-Raman spectra were recorded
on a Bruker MultiRAM FT-Raman spectrometer (Bruker AG, F&#x000e4;llanden,
Switzerland) with a near-infrared Nd/YAG laser operating at 1064 nm
and a liquid-nitrogen-cooled germanium detector. A total number of
64 scans with a resolution of 2 cm<sup>&#x02013;1</sup> was accumulated
in the range from 50 to 3500 cm<sup>&#x02013;1</sup> using a nominal
laser power of 100 mW. The samples were prepared by pressing the isolated
powder into an aluminum sample holder.</p></sec><sec id="sec2.10"><title>Powder X-ray Diffraction</title><p>Diffractograms for the high-throughput
plate from HTS-2 were collected using a PANalytical X&#x02019;Pert
PRO-MPD diffractometer (Malvern Panalytical Ltd., Malvern, United
Kingdom) equipped with a PIXCEL detector operating with Cu K<sub>&#x003b1;,1</sub> radiation. The measurements were performed in reflection mode using
a tube voltage of 45 kV and a current of 40 mA, Soller slit: 0.04,
Ni-Filter 0.02 mm, Inc. Mask Fixed 5 mm (MPD/MRD). A step size of
0.013&#x000b0;2&#x003b8; and a step time of 40.8 s over a 2&#x02013;34&#x000b0;2&#x003b8;
scanning range were applied. The solid residues of HTS-2 were analyzed
by covering the plate with a Kapton foil and by elevating the base
of the wells. All sample preparations and measurements were done at
RT in an ambient air atmosphere.</p><p>Diffractograms of LAG and reaction
crystallization samples were collected using a Stoe Stadi P diffractometer
(Stoe &#x00026; Cie. GmbH, Darmstadt, Deutschland) equipped with a Mythen1K
detector operating with Cu K<sub>&#x003b1;,1</sub> radiation. The measurements
were performed in transmission mode with a tube voltage of 40 kV and
a current of 40 mA. A step size of 0.02&#x000b0;2&#x003b8; and a step time
of 12 s over a 1.5&#x02013;50.5&#x000b0;2&#x003b8; scanning range were applied.
For a typical sample preparation, about 10&#x02013;20 mg of the sample
was placed between two acetate foils and mounted into a Stoe transmission
sample holder. The sample was rotated during the measurement. All
sample preparation and measurement were performed at RT in an ambient
air atmosphere.</p><p>Diffractograms of the residual solids after
dissolution experiments
were collected by using a Rigaku Miniflex600 diffractometer (Rigaku
Corporation, Tokyo, Japan) equipped with a scintillation (NaI) counter
detector operating with Cu K<sub>&#x003b1;,1</sub> radiation. The measurements
were performed in reflection mode with a &#x003b8;/2&#x003b8; geometry,
at a tube voltage of 40 kV, and a current of 40 mA. A step size of
0.02&#x000b0;2&#x003b8; and a scanning speed of 5&#x000b0;2&#x003b8;/min over
a 3&#x02013;30&#x000b0;2&#x003b8; scanning range were applied. For a typical
sample preparation, 10&#x02013;20 mg of powder was added to a sample
holder and flattened with the help of a glass slide.</p></sec><sec id="sec2.11"><title>Thermogravimetry
Coupled with Fourier Transform Infrared Spectroscopy</title><p>TG-FTIR
spectroscopy was performed on a NETZSCH TG 209F1 Libra
instrument (Netzsch, Selb, Germany), which was coupled to a Bruker
FT-IR Tensor II spectrometer. Around 5 mg of powder was loaded into
an aluminum crucible with a (micro) pinhole, and the measurements
were carried out under a nitrogen atmosphere and at a heating rate
of 10 &#x000b0;C/min over the range of 25&#x02013;300 &#x000b0;C.</p></sec><sec id="sec2.12"><title>Proton
Nuclear Magnetic Resonance (<sup>1</sup>H NMR)</title><p>
<sup>1</sup>H NMR analysis was carried out with a Bruker DPX300 spectrometer
(Bruker AG, F&#x000e4;llanden, Switzerland) using a proton frequency
of 300.13 MHz, a 30&#x000b0; excitation pulse, and a recycle delay of
1 s. Spectra were recorded by accumulation of 16 scans in deuterated
DMSO at 298 K. The solvent peak was used for referencing, and the
chemical shifts were reported on the tetramethylsilane (TMS) scale.</p></sec><sec id="sec2.13"><title>Differential Scanning Calorimetry</title><p>DSC analyses were
carried out with a TA Instruments Q2000 or with a TA Instruments DSC
2500 instrument (TA Instruments, New Castle, Delaware, USA). Approximately
2&#x02013;3 mg of the sample was heated at a rate of 10 K/min under
a nitrogen gas flow (50 mL/min). Standard aluminum sample pans that
were hermetically closed were used for the measurements.</p></sec><sec id="sec2.14"><title>Ultra-high-Performance
Liquid Chromatography Coupled with UV&#x02013;Vis
Detection</title><p>CILP and TSA were quantified by UHPLC-UV. The UHPLC-UV
system (Thermo Fisher Scientific, Massachusetts, USA) consists of
an UltiMate Rapid Separation Autosampler (WPS-3000RS), an UltiMate
Rapid Separation Thermostated Column Compartment (TCC-3000RS), as
well as an UltiMate Rapid Separation UHPLC Diode Array Detector (DAD-3000RS).
A Kinetex EVO-C18 column (1.7 &#x003bc;m, 2.1 mm &#x000d7; 100 mm) was
used for the separation and kept at a temperature of 40 &#x000b0;C. An
isocratic method was employed for the quantification of cilnidipine
in dissolution samples in blank FaSSIF. The mobile phase consisted
of acetonitrile (70% v/v) and water with 0.1% trifluoroacetic acid
(TFA) (30% v/v). Cilnidipine eluted after 2.1 min and was quantified
at 240 nm. A calibration curve was built using concentrations from
0.01 to 1 &#x003bc;g/mL. A gradient method was employed for the quantification
of cilnidipine in dissolution samples in FaSSIF and TSA. The mobile
phase consisted of acetonitrile and water with 0.1% TFA with an elution
gradient from 40:60 to 80:20 acetonitrile/water over 1.5 min. An 80:20
ratio was maintained until 4 min and was then changed to 40:60 over
1 min. The system was subsequently equilibrated at a 40:60 acetonitrile/water
composition for 5 min. TSA eluted after 1.6 min and CILP after 3.9
min; the compounds were quantified at 224 and 240 nm, respectively.
In both methods, a volume of 5 &#x003bc;L was injected and run at a
flow rate of 0.3 mL/min.</p></sec><sec id="sec2.15"><title>Computational Cocrystal Screening</title><sec id="sec2.15.1"><title>Molecular
Complementarity</title><p>The MC analysis was carried
out with the CSD-material package supplied in Mercury 2024.2.0 (Cambridge,
UK). The analysis was developed by L. F&#x000e1;bi&#x000e1;n based on
the finding that molecules that cocrystallize tend to have similar
shapes and polarities.<xref rid="ref13" ref-type="bibr"/> To evaluate molecular
similarity, 5 molecular descriptors are used: two are related to the
polarity of the molecule, namely, fraction of nitrogen and oxygen
atoms (FNO) and dipole moment; three are related to the shape and
are defined considering the short (<italic toggle="yes">S</italic>), medium (<italic toggle="yes">M</italic>), and long (<italic toggle="yes">L</italic>) axes of a box enclosing
the van der Waals molecular volume, namely, the <italic toggle="yes">S</italic> axis, <italic toggle="yes">M</italic>/<italic toggle="yes">L</italic> axis ratio, and <italic toggle="yes">S</italic>/<italic toggle="yes">L</italic> axis ratio (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>). Since the API employed in this study is
a large and flexible molecule, the possible conformations in the crystal
can vary significantly, leading to different molecular descriptors.
To account for these variations, ten likely conformations of the API
were generated via the &#x0201c;Conformer generation&#x0201d; function
in Mercury 2024.2.0 (Cambridge, UK), starting from the 2D molecular
structure of cilnidipine. Generally, one 3D conformation was used
for rigid coformers, while three different conformations were generated
for flexible coformers. The five molecular descriptors for each conformation
of API and coformer were calculated with the CSD-material package
supplied in Mercury 2024.2.0 (Cambridge, UK). The molecular descriptors
were employed to calculate a normalized complementarity score for
each API&#x02013;coformer pair. As reported by F&#x000e1;bi&#x000e1;n
and Fri&#x00161;&#x0010d;i&#x00107;,<xref rid="ref14" ref-type="bibr"/> the
complementarity score is calculated in <xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula"/>
</xref> by dividing the difference between the API
(<italic toggle="yes">X</italic>
<sub>D,API</sub>) and the cocrystal former descriptors
(<italic toggle="yes">X</italic>
<sub>D,cof</sub>) by the cutoff value (&#x003b4;<sub>D</sub>) and summing the results for each descriptor (D). The cutoff
values were defined by F&#x000e1;bi&#x000e1;n from a statistical analysis
conducted on cocrystals reported in the CSD; the cutoff values for
molecular descriptors are defined such that 90% of cocrystals contained
in the analysis exhibit a difference in the molecular descriptor that
is lower than the cutoff value.<xref rid="ref14" ref-type="bibr"/> The complementarity
score is calculated pairwise for each conformation of cilnidipine
and coformer and is then averaged over the 10 conformations of API
and the 1&#x02013;3 conformations of coformer. Different conformations
of API and coformers were considered because they might be adopted
in the cocrystal. The lower the complementarity score, the larger
the similarity between the two molecules and the greater their ability
to cocrystallize.<disp-formula id="eq1">
<label>1</label>
<alternatives><graphic xlink:href="cg5c00184_m001.jpg" position="float"/><mml:math id="d1e608" display="block" overflow="scroll"><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo>&#x02211;</mml:mo><mml:mi mathvariant="normal">D</mml:mi></mml:munder><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:msub></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>M</mml:mi><mml:mo>/</mml:mo><mml:mi>L</mml:mi></mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mn>0.31</mml:mn></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mn>3.23</mml:mn></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:mrow><mml:mi>S</mml:mi><mml:mo>/</mml:mo><mml:mi>L</mml:mi></mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mn>0.28</mml:mn></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mn>5.94</mml:mn></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mn>0.29</mml:mn></mml:mfrac></mml:mrow></mml:math></alternatives>
</disp-formula>
</p><p>Alternatively, the molecular descriptors
can be used in the &#x0201c;default settings analysis&#x0201d; available
in Mercury (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>). The analysis is usually implemented as a PASS/FAIL test; it predicts
cocrystal formation if, and only if, the difference between the API
and coformer descriptors is within the cutoff value for all five descriptors.
A percentage hit rate is computed for each coformer and is averaged
over the number of API conformations screened.</p></sec><sec id="sec2.15.2"><title>COSMO-RS,
&#x003c3;-Surfaces, and &#x003c3;-Profiles</title><p>The
COnductor-like Screening Model for Real Solvents (COSMO-RS) is a liquid-phase
thermodynamic theory used to accurately calculate thermodynamic properties
in solution.<xref rid="ref19" ref-type="bibr"/> The molecules are placed
in a virtual dielectric continuum, and the polarization charge density
(&#x003c3;) on the molecular surface, the so-called &#x003c3;-surface,
is calculated by DFT calculations.<xref rid="ref15" ref-type="bibr"/> The
strength of the theory is the computation of intermolecular interactions
as local contacts on the &#x003c3;-surface by statistical thermodynamic
calculations of pairwise interactions of surface segments;<named-content content-type="bibref-group">
<xref rid="ref18" ref-type="bibr"/>,<xref rid="ref19" ref-type="bibr"/>
</named-content> hydrogen bonding, van der Waals, and electrostatic interactions
are accurately evaluated in this way. For computation, the &#x003c3;-surface
is represented by a histogram of segmental screening charge densities,
which is called the &#x003c3;-profile. The calculation of intermolecular
interactions leads to the determination of the energy and the chemical
potential of the system, from which thermodynamic properties can be
derived.<xref rid="ref28" ref-type="bibr"/>
</p></sec><sec id="sec2.15.3"><title>COSMOquick Screening</title><p>Since COSMO-RS is a liquid-phase
thermodynamic theory, it is assumed that the interactions in a crystal
are similar to those in a supercooled liquid. The strength of interactions
between two components can be estimated by the excess or mixing enthalpy
(&#x00394;<italic toggle="yes">H</italic>
<sub>mix</sub>) of an API&#x02013;coformer
pair under supercooled conditions compared to the pure components.<named-content content-type="bibref-group">
<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref17" ref-type="bibr"/>
</named-content> The mixing enthalpy is a rough approximation of the free energy
of cocrystal formation (&#x00394;<italic toggle="yes">G</italic>
<sub>cc</sub>), as
presented in <xref rid="eq2" ref-type="disp-formula">eq <xref rid="eq2" ref-type="disp-formula"/>
</xref>.<disp-formula id="eq2">
<label>2</label>
<alternatives><graphic xlink:href="cg5c00184_m002.jpg" position="float"/><mml:math id="d1e795" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02248;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:math></alternatives>
</disp-formula>
</p><p>The difference between the energy of
fusion of the cocrystal and reactants, &#x00394;&#x00394;<italic toggle="yes">G</italic>
<sub>fus</sub>, representing the long-range and packing contribution
to cocrystallization, is assumed to be negligible by this approach,
and at supercooled conditions the entropy term is assumed to be negligible.
The tendency of an API&#x02013;coformer pair to form a cocrystal is
evaluated by the screening function <italic toggle="yes">F</italic>
<sub>screen</sub>. This function accounts not only for the molecular interactions
(&#x00394;<italic toggle="yes">H</italic>
<sub>mix</sub>) but also for the flexibility
of the molecule in the form of the number of rotatable bonds.<named-content content-type="bibref-group">
<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref17" ref-type="bibr"/>
</named-content> The screening function is reported in <xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula"/>
</xref>, where <italic toggle="yes">a</italic> is a fit parameter
to be determined on a set of experimental results, and <italic toggle="yes">n</italic> is the total number of rotatable bonds of the drug and the coformer. <italic toggle="yes">F</italic>
<sub>screen</sub> is related to the tendency of cocrystal
formation because it accounts for the mixing enthalpy (&#x00394;<italic toggle="yes">H</italic>
<sub>mix</sub>) of a coformer-API pair but, in addition,
penalizes floppy molecules, as it was observed experimentally that
they hinder cocrystal formation.<named-content content-type="bibref-group">
<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref17" ref-type="bibr"/>
</named-content> The lower
the <italic toggle="yes">F</italic>
<sub>screen</sub> value for a coformer-API pair,
the higher the likelihood of cocrystal formation.<disp-formula id="eq3">
<label>3</label>
<alternatives><graphic xlink:href="cg5c00184_m003.jpg" position="float"/><mml:math id="d1e913" display="block" overflow="scroll"><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>max</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>max</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives>
</disp-formula>
</p><p>COSMOquick speeds up the calculation
of &#x003c3;-surfaces by combining
surface fragments from a database of precomputed molecules. The database
contains precomputed &#x003c3;-surfaces at the BP-TZVP-COSMO level.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/>&#x02212;<xref rid="ref30" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref31" ref-type="bibr"/>
</named-content> The virtual cocrystal screening of cilnidipine was performed using
the COSMOquick software v.2020 (Dassault Syst&#x000e8;mes/Biovia) on
a list of 140 compounds by selecting a 1:1 CILP/coformer stoichiometry.
The 1:1 ratio was selected for the screening because it is the most
common cocrystal stoichiometry. A list of Simplified Molecular Input
Line-Entries (SMILES) of CILP and the coformers was employed as input
for the calculation. Most of the coformers&#x02019; &#x003c3;-profiles
were available in the compound database, while approximate &#x003c3;-profiles
were generated for CILP by COSMOfrag. The statistical thermodynamic
calculations were carried out by using the COSMOtherm code. The output
resulted in a list of coformers ranked according to the values of
the penalty function (<italic toggle="yes">F</italic>
<sub>screen</sub>) or the
excess enthalpy (&#x00394;<italic toggle="yes">H</italic>
<sub>mix</sub>) of the corresponding
cocrystals with cilnidipine.</p></sec></sec></sec><sec id="sec3"><title>Results and Discussion</title><sec id="sec3.1"><title>Experimental
Cocrystal Screening</title><p>The CILP-TSA cocrystal
was discovered both by &#x0201c;manual&#x0201d; and &#x0201c;semi-automatic&#x0201d;
high-throughput screening methods (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>). The starting CILP powder was an anhydrous
racemate, as its diffraction pattern matched that calculated from
the previously determined crystal structure [CCDC reference 2215828].<xref rid="ref32" ref-type="bibr"/> Although a second polymorph of the compound
has been reported,<xref rid="ref33" ref-type="bibr"/> it was not observed
in this study. In addition, since photodegradation of cilnidipine
was described in concentrated solutions in methanol,<xref rid="ref34" ref-type="bibr"/> precautions were taken to prevent light exposure during
crystallization experiments.</p><fig position="float" id="fig2" fig-type="figure"><label>2</label><caption><p>Schematic representation of the two high-throughput
screening approaches
(HTS-1 and HTS-2) employed in this study. The term &#x0201c;Reaction
c.&#x0201d; is an abbreviation of &#x0201c;reaction crystallization&#x0201d;.</p></caption><graphic xlink:href="cg5c00184_0002" id="gr2" position="float"/></fig><p>Coformers were selected through a prospective computational
approach
performed with the COSMOquick method: the top-ranked 52 coformers
available in the laboratory were employed in the HTS (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). Coformers were tested experimentally
by solution-based methods such as evaporation and slurry equilibration.
To increase the likelihood of cocrystallization, replicates were performed
in different solvents (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Figures S1, S2</ext-link>). Indeed, cocrystal
stability and formation strongly depend on the relative solubility
of the API and coformer in the solvent used.<xref rid="ref35" ref-type="bibr"/>
</p><p>The first approach (HTS-1) involved manual operations for
the dispersion
and addition of solvents and the detection of crystals. Indeed, new
solid phases were identified by looking for crystals in the wells
and collecting Raman spectra using a Raman microscope. The presence
of new features in the Raman spectrum indicates the formation of new
interactions in the solid phase. A strong lead for a potential cocrystal
was obtained with <italic toggle="yes">p</italic>-toluenesulfonamide (TSA) because
both crystals with new morphology (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>) and a new Raman spectrum (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>a) were observed in multiple wells: i.e., evaporation
experiments with THF and slurry equilibration with <italic toggle="yes">tert</italic>-butyl methyl ether (TBME), ethanol (EtOH), and methanol (MeOH).
Only weak leads were obtained with a few of the other coformers (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Figure S1</ext-link> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S1</ext-link>) because only one or two additional low-intensity peaks were observed
in a single solvent.</p><fig position="float" id="fig3" fig-type="figure"><label>3</label><caption><p>(a) Overlay of Raman spectra and (b) overlay of diffraction
patterns.
From the bottom, <italic toggle="yes">p</italic>-toluenesulfonamide (yellow), cilnidipine
(red), CILP-TSA HTS-1 experiment&#x0e5f8;well G4 (purple-Raman), CILP-TSA
HTS-2 experiment&#x0e5f8;well F1 (purple-PXRD), and CILP-TSA cocrystal
(blue).</p></caption><graphic xlink:href="cg5c00184_0003" id="gr3" position="float"/></fig><p>Based on these observations, a
second HTS approach
(HTS-2) was
conducted on 21 new coformers with the addition of TSA and naphthalene-2-sulfonamide
as positive and negative controls, respectively, in order to confirm
the HTS-1 results. The HTS-2 approach involves automatic operations
performed by a robotic system (e.g., dispensing of solution, evaporation,
and shaking) and allows the analysis of the solid residues directly
by PXRD. Similarly to HTS-1, strong leads of HTS-2 were observed only
with TSA. A new diffraction pattern, overlapping with low-angle CILP
reflections, was observed in multiple wells containing the coformer
TSA (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig"/>
</xref>b and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">S2</ext-link>), indicating the presence of a new crystal
phase. Weak leads were observed with amino acids, such as glycine, <sc>l</sc>-valine, and <sc>l</sc>-alanine. These results confirmed that
using a semiautomatic HTS approach leads to the same identification
of TSA as the manual one with the advantage of an accelerated screening
time.</p><p>It is worth noting that some crystallization experiments,
both
in HTS-1 and HTS-2, resulted in the formation of a transparent and
yellowish amorphous material, especially by evaporation from acetone
and THF. The precipitation of the amorphous phase might be due to
the nature of cilnidipine, which is reported to be a slow crystallizer
from the melt<named-content content-type="bibref-group">
<xref rid="ref36" ref-type="bibr"/>,<xref rid="ref37" ref-type="bibr"/>
</named-content> or due to fast evaporation conditions.
Furthermore, the presence of the coformer may result in the formation
of a coamorphous system with high kinetic stability rather than a
cocrystal.<xref rid="ref25" ref-type="bibr"/>
</p><p>Since cocrystal formation
may occur only with specific crystallization
methods and conditions, the HTS findings with TSA and other weak lead
coformers were reproduced at the 100 mg scale by liquid-assisted grinding
(LAG) and reaction crystallization experiments (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). LAG is a mechanochemical method that has previously
proven to be successful in occasions in which the solvent-based methods
failed.<xref rid="ref8" ref-type="bibr"/> In addition, reaction crystallization
experiments at RT were performed by using a nearly saturated solution
of the coformer to facilitate access to the stability region of the
cocrystal.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>,<xref rid="ref35" ref-type="bibr"/>
</named-content> A new crystal phase was observed only with
TSA using three different crystallization methods (LAG, reaction crystallization,
and evaporation) and two different solvents (i.e., ethanol and acetonitrile),
while physical mixtures were obtained with the other coformers.</p><p>The newly discovered phase is a 1:1 CILP&#x0e5f8;TSA cocrystal (see
the &#x0201c;<xref rid="sec3.2" ref-type="sec">Co-crystal Characterization</xref>&#x0201d;
section). The characteristic Raman spectrum and diffraction pattern
of the cocrystal perfectly overlap with the features observed in the
HTS experiments, as demonstrated by the Raman peaks at 1155, 1476,
and 1690 cm<sup>&#x02013;1</sup> and by the powder X-ray reflections
at 4.7, 9.4, and 12.2&#x000b0;2&#x003b8; (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>), further corroborating the high-throughput
screening results.</p><p>These findings indicate that new cocrystals
of an API can also
be identified using a more automated HTS approach (HTS-2) in addition
to the standard manual approach (HTS-1). The advantages of the semiautomated
HTS-2 approach are the reduced user operation and faster analysis
time of the entire well with PXRD. On the other hand, the manual HTS-1
approach allows for a more accurate investigation of the individual
crystalline materials in the wells and for identification of complexation
as amorphous materials using Raman microscopy.</p></sec><sec id="sec3.2"><title>Cocrystal Characterization</title><p>The discovered multicomponent
crystal of CILP with <italic toggle="yes">p</italic>-toluenesulfonamide (CILP-TSA)
was obtained through the reaction crystallization method in ethanol.
Due to the neutral nature of both CILP and TSA, the multicomponent
crystal must be a cocrystal rather than a salt. The crystals of CILP-TSA
display a bright yellow color compared with the pale-yellow crystalline
powder of CILP (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>a,b). The cocrystal is characterized by a 1:1 stoichiometry of the
components, as determined by <sup>1</sup>H NMR spectroscopy and UHPLC-UV
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Figure S7</ext-link> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S5</ext-link>). The DSC thermogram of CILP-TSA shows one endothermic event
at 122.6 &#x000b0;C corresponding to the cocrystal melting point (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>c), which is located
in between the ones of CILP (105.8 &#x000b0;C) and TSA (137.7 &#x000b0;C).<xref rid="ref38" ref-type="bibr"/> TG-FTIR analysis revealed that the cocrystal
is anhydrous; no mass loss was detected before the degradation of
the components at 250 &#x000b0;C (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Figure S6</ext-link>). The presence of new features in the Raman spectrum of the CILP-TSA
cocrystal (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>a) indicates the formation of intermolecular interactions, such as
hydrogen bonds, between the API and coformer in the solid state. The
Raman spectrum of crystalline CILP (red in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>a) is characterized by the C&#x0e5fb;O carbonyl
stretching vibration of the ester group at 1700 cm<sup>&#x02013;1</sup>,<xref rid="ref23" ref-type="bibr"/> the C&#x0e5fb;C stretching vibrations
of the aromatic rings, the conjugated double bond and the dihydropyridine
ring (1661, 1644, and 1600 cm<sup>&#x02013;1</sup>), the symmetrical
stretching of the NO<sub>2</sub> group at 1350 cm<sup>&#x02013;1</sup>,<named-content content-type="bibref-group">
<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content> and the&#x0e5fb;C&#x02013;H in-plane deformation
vibrations of the aromatic rings at 1002 cm<sup>&#x02013;1</sup> and
1030 cm<sup>&#x02013;1</sup>.<named-content content-type="bibref-group">
<xref rid="ref23" ref-type="bibr"/>,<xref rid="ref41" ref-type="bibr"/>
</named-content> In addition to the
features of CILP, the Raman spectrum of the cocrystals (blue in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>a) shows a shift
in the C&#x0e5fb;O carbonyl stretching frequency of the ester group
(1690 cm<sup>&#x02013;1</sup>), a new broad band at 946 cm<sup>&#x02013;1</sup>, which may be associated with C&#x02013;O&#x02013;C stretching vibration
of the aliphatic ether group, and the S&#x0e5fb;O symmetric stretching
of the sulfonamide moiety of TSA at 1155 cm<sup>&#x02013;1</sup>.<named-content content-type="bibref-group">
<xref rid="ref41" ref-type="bibr"/>,<xref rid="ref42" ref-type="bibr"/>
</named-content> These features suggest the formation of intermolecular interactions
in the solid state between the ester and ether groups of CILP and
the sulfonamide group of TSA.</p><fig position="float" id="fig4" fig-type="figure"><label>4</label><caption><p>(a) Picture presenting the pale-yellow powder
of crystalline CILP;
(b) picture presenting the bright-yellow crystalline powder of the
CILP-TSA cocrystal; (c) DSC thermograms of crystalline CILP, TSA,
and the CILP-TSA cocrystal (enthalpy of fusion is reported in the
Supporting Information, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S4</ext-link>).</p></caption><graphic xlink:href="cg5c00184_0004" id="gr4" position="float"/></fig><p>
<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref> (left-hand
side) presents the cocrystal dissolution profiles in blank FaSSIF
pH 6.5 and FaSSIF pH 6.5. The standard FaSSIF medium differs from
blank FaSSIF, a plain phosphate buffer, by the presence of the biorelevant
surfactant lecithin and the bile salt sodium taurocholate. The cocrystal
achieves maximum concentrations in solution that are 6.5 times (blank
FaSSIF) and 4 times (FaSSIF) above the solubility of the crystalline
drug. After maximum supersaturation is achieved&#x0e5f8;which is after
4 h in blank FaSSIF and 3 h in FaSSIF&#x0e5f8;a slow decrease in concentration
corresponding to precipitation of the crystalline drug is observed.
Supersaturation is still sustained after 8 h from the beginning of
the dissolution experiment. The dissolution profile in FaSSIF pH 6.5
mimics how the cocrystal would dissolve in the small intestine after
administration with a glass of water. Higher drug solubility is reported
in this medium due to the presence of amphiphilic molecules (sodium
taurocholate and lecithin), which form mixed micelles that are able
to solubilize CILP (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>).</p><fig position="float" id="fig5" fig-type="figure"><label>5</label><caption><p>(a) Left: co-crystal dissolution profile in blank FaSSIF pH 6.5;
right: comparison of CILP and TSA bulk concentrations during cocrystal
dissolution (note the different scales and units of the vertical axes);
(b) left: cocrystal dissolution profile in FaSSIF pH 6.5; right: comparison
of CILP and TSA bulk concentrations during cocrystal dissolution.
Data are plotted as mean value (<italic toggle="yes">n</italic> = 3) &#x000b1; standard
deviation, which is represented by the error bars. The dashed black
line represents the solubility of crystalline cilnidipine in the dissolution
medium. No change in pH in the media was measured after 24 h.</p></caption><graphic xlink:href="cg5c00184_0005" id="gr5" position="float"/></fig><table-wrap position="float" id="tbl2"><label>2</label><caption><title>Solubility of Cilnidipine in Blank
FaSSIF and FaSSIF pH 6.5 in the Presence and Absence of the Dissolved
Coformer at 37 &#x000b0;C<xref rid="t2fn1" ref-type="table-fn"/>
</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/></colgroup><thead><tr><th align="center">&#x000a0;</th><th align="center" char="&#x000b1;">solubility blank FaSSIF
(&#x003bc;M)</th><th align="center" char="&#x000b1;">solubility FaSSIF (&#x003bc;M)</th></tr></thead><tbody><tr><td align="left">CILP</td><td align="char" char="&#x000b1;">(4.6&#x000a0;&#x000b1;&#x000a0;0.6)&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;2</sup>
</td><td align="char" char="&#x000b1;">25.0&#x000a0;&#x000b1;&#x000a0;3.9</td></tr><tr><td align="left">CILP (+200&#x000a0;&#x003bc;g/mL&#x000a0;TSA)</td><td align="char" char="&#x000b1;">(5.0&#x000a0;&#x000b1;&#x000a0;0.4)&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;2</sup>
</td><td align="char" char="&#x000b1;">29.9&#x000a0;&#x000b1;&#x000a0;3.0</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>The tested coformer concentration
(200 &#x003bc;g/mL, 1.16 mM) is five times higher than the maximum concentration
achievable during the dissolution studies (43 &#x003bc;g/mL, 0.25 mM).
Values are presented as mean (<italic toggle="yes">n</italic> = 3) &#x000b1; standard
deviation. The final measured pH was 6.5.</p></fn></table-wrap-foot></table-wrap><p>The supersaturation achieved through cocrystal dissolution
in FaSSIF
results in potentially increased drug absorption in vivo compared
to the crystalline drug.</p><p>
<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref> reports
no significant difference (<italic toggle="yes">p</italic> &#x0003e; 0.05) between the
drug solubility values measured in the absence and presence of coformer,
confirming that no interactions between CILP and TSA are present in
solution. Since no complexation with the coformer takes place in solution,
the drug supersaturation achieved by this cocrystal is purely dependent
on the properties of the multicomponent crystal.</p><p>Insights into
the cocrystal dissolution&#x02013;supersaturation&#x02013;precipitation
(DSP) behavior can be gained by comparing CILP and TSA bulk concentrations
during dissolution as reported on the right side of <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>a (blank buffer) and <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>b (FaSSIF). Theoretically,
due to the nature of the crystal phase, cocrystals dissolve congruently
according to their stoichiometry. For instance, the CILP-TSA cocrystal,
characterized by a 1:1 stoichiometry of the components, would release
one millimole of CILP for every millimole of TSA into the dissolution
medium. However, <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>a shows that, already after 5 min of dissolution in blank FaSSIF,
the bulk molar concentration of TSA (3.05 &#x003bc;M) is more than 100
times higher than that of CILP (0.01 &#x003bc;M). This behavior may
be explained by a rapid cocrystal dissolution that generates high
supersaturation adjacent to the surface of the cocrystal particles,
while the bulk concentration is still below the drug solubility. The
supersaturation on the surface of the cocrystal is the driving force
for heterogeneous nucleation of CILP crystals.<xref rid="ref43" ref-type="bibr"/> Examples of surface-nucleating cocrystals have been reported
in the case of carbamazepine (CBZ), where needle-like crystals of
CBZ grew on the surface of several cocrystals of the drug.<named-content content-type="bibref-group">
<xref rid="ref44" ref-type="bibr"/>,<xref rid="ref45" ref-type="bibr"/>
</named-content> The process can be regarded as a particle surface-solution-mediated
phase transformation (PS-SMPT).</p><p>Despite the nucleation of crystalline
cilnidipine, the bulk CILP
concentration continued to increase, reaching a critical value of
0.3 &#x003bc;M after 4 h, corresponding to a supersaturation of 6.5.
This maximum concentration marks the critical supersaturation at which
the bulk growth of cilnidipine crystals occurs, and precipitation
begins to outcompete cocrystal dissolution.</p><p>
<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>b shows
a different dissolution behavior of the cocrystal in FaSSIF. A stoichiometric
ratio of CILP to TSA is observed in the bulk solution up to nearly
3 h, when the maximum supersaturation is reached. These results suggest
sustained congruent dissolution over a prolonged time. Nucleation
and growth of CILP crystals occur in the bulk solution, triggered
by reaching the critical supersaturation value. The different cocrystal
dissolution behavior observed in blank FaSSIF and FaSSIF can be explained
by the presence of surfactant micelles in FaSSIF. Lipert et al. showed
that surfactant micelles reduce the achievable cocrystal solubility
advantage (ratio of cocrystal to drug solubility) and, hence, the
driving force for precipitation.<xref rid="ref46" ref-type="bibr"/> The
presence of micelles, able to solubilize the drug molecules, may decrease
the rate of supersaturation, preventing fast nucleation of crystalline
CILP around the cocrystal surface. Bile salts and lecithin, present
in FaSSIF, may also act as precipitation inhibitors for crystalline
CILP.</p><p>In addition, the faster dissolution of the cocrystal in
FaSSIF
as compared to blank buffer, evaluated by the dissolved concentration
of TSA, may be explained by better wettability of the crystals and
higher affinity of CILP for the medium: the solubility of CILP in
FaSSIF is 600 times the one observed in blank FaSSIF (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>).</p><p>The final solid residues
collected at the end of the experiment
confirmed the reprecipitation of crystalline CILP (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>). Poor wettability of the
cocrystal powder and agglomeration during the dissolution in blank
FaSSIF resulted in only a third of the cocrystal dissolving after
24 h (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S6</ext-link>). <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref> shows that most of the solid residue collected
after dissolution in blank FaSSIF belongs to the cocrystal. The better
powder wettability achieved in FaSSIF and the lack of rapid heterogeneous
nucleation on the crystal surface resulted in an almost complete dissolution
of the cocrystal (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S6</ext-link>).</p><fig position="float" id="fig6" fig-type="figure"><label>6</label><caption><p>Overlay of
diffraction patterns of the solid residues collected
after dissolution studies and CILP-TSA and CILP. From the bottom:
cilnidipine (red), CILP-TSA (blue), solid residue after dissolution
in blank FaSSIF (green), and solid residue after dissolution in FaSSIF
(purple).</p></caption><graphic xlink:href="cg5c00184_0006" id="gr6" position="float"/></fig><sec id="sec3.2.1"><title>Computational Cocrystal Screening</title><p>Computational tools
can be employed prior to the experimental cocrystal screening to rank
the most promising coformers from a library of compounds. The purpose
of this approach is to reduce the number of experiments and increase
the efficiency of cocrystal formation by testing the top-ranked coformers
first. In this study, two computational methods, Molecular Complementarity
(MC) and COSMOquick, were employed to rank coformers in the cocrystal
screening of cilnidipine. The prediction performance of the two methods
was then evaluated based on the experimental findings.</p><p>MC revealed
an excellent prediction ability in selecting the best coformers for
CILP, because TSA, the only coformer resulting in a cocrystal to date,
was ranked third out of 52 compounds (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Tables S1 and S2</ext-link>). In contrast, COSMOquick ranked TSA in the middle of
the screening list (22nd out of 52). Since TSA is the third-ranked
coformer, the use of MC to preselect most likely coformers would have
reduced the number of experiments required to discover a cocrystal.
Cocrystal formation depends on both the intermolecular interactions
between the components and the packing contributions to the long-range
order. Therefore, the difference in prediction performance of the
two computational methods may be related to the approach used: MC
considers the similarity in shape and polarity of the API&#x02013;coformer
pairs, while COSMOquick considers the van der Waals and electrostatic
interactions between them.</p><p>The worse performance achieved with
COSMOquick might be explained
by two factors: (1) the approximations included in the method and
(2) the incorrect representation of the cilnidipine molecule by the
COSMOquick fragmentation approach.</p><p>COSMOquick assumes that the
interactions in the cocrystals are
similar to a supercooled liquid phase.<xref rid="ref16" ref-type="bibr"/> For this reason, the approach ranks coformers according to their
&#x0201c;miscibility&#x0201d; with cilnidipine (&#x00394;<italic toggle="yes">H</italic>
<sub>mix</sub>), namely, the strength of interactions with the API
compared to those of the two pure components in the supercooled liquid.
The method neglects the contributions of crystal packing and long-range
order to cocrystal formation (&#x00394;&#x00394;<italic toggle="yes">G</italic>
<sub>fus</sub> term in <xref rid="eq2" ref-type="disp-formula">eq <xref rid="eq2" ref-type="disp-formula"/>
</xref>) that may prevent the formation of some interactions. Despite the
approximation, the method was successfully tested on different cocrystal
cases.<named-content content-type="bibref-group">
<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref17" ref-type="bibr"/>
</named-content> Nevertheless, crystal packing contributions
may be more relevant for large and flexible molecules and, hence,
cannot be neglected in the prediction of cocrystals. This is possibly
the case for cilnidipine, where the approximations lead to an incorrect
ranking of the TSA.</p><p>An additional reason for the incorrect ranking
could be due to
the &#x003c3;-surface of cilnidipine. The &#x003c3;-surface represents
the polarization charge density surface and is employed in the calculation
of intermolecular interactions (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>): the more imprecise the &#x003c3;-surface representation,
the less accurate the estimation of the intermolecular interactions
will be. In COSMO-RS, the &#x003c3;-surfaces are obtained through DFT
calculations, but COSMOquick, in order to reduce computational time,
generates them by combining one or more precomputed fragments from
a database.</p><fig position="float" id="fig7" fig-type="figure"><label>7</label><caption><p>COSMOquick precomputed fragments employed to build the &#x003c3;-surface
of cilnidipine. Areas with positive polarization charge density are
highlighted in red (H-bond acceptor), while areas with negative polarization
charge density are highlighted in blue (H-bond donor).</p></caption><graphic xlink:href="cg5c00184_0007" id="gr7" position="float"/></fig><p>The &#x003c3;-surfaces of the coformers employed
in the study were
already present in the COSMOquick database, but the &#x003c3;-surface
of cilnidipine was obtained by combining two different fragments,
which cut the dihydropyridine ring in two parts (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>). The fragmentation may lead
to an incorrect representation of the polarization charge density
of the dihydropyridine ring and of the hydrogen bond donor (N&#x02013;H).
This could result in an erroneous estimation of interactions with
the coformers. The importance of the N&#x02013;H group is shown by
the crystal structures of cilnidipine and other dihydropyridines (e.g.,
nifedipine [CCDC reference 2263411]), where monodimensional N&#x02013;H&#x02013;O
hydrogen-bonded chains dominate the crystal packing.<xref rid="ref32" ref-type="bibr"/> In addition, the &#x003c3;-surface of the COSMOquick approach
does not account for the different possible conformations of cilnidipine,
which can be otherwise considered in the more laborious COSMOtherm
calculations.</p><p>Therefore, the use of COSMOquick as a screening
tool for promising
coformers is suggested when the &#x003c3;-surface of the API is not
subjected to fragmentation but has been previously calculated at a
quantum chemical level or when the fragmentation occurs far from H-bond
donors or acceptors.</p><p>It is worth mentioning that the COSMOquick
ranking may be used
as a screening method for the prediction of coamorphous systems. Indeed,
differently from the crystal phase, packing contributions and solid-state
order are negligible in the amorphous phase. In the experimental HTS
of CILP, an amorphous material was observed in the presence of some
coformers. However, testing such an approach would be beyond the scope
of this paper.</p><p>On the contrary, packing contributions might
be caught by MC through
the calculation of the complementarity score (<italic toggle="yes">C</italic>
<sub>score</sub>). Indeed, coformers are ranked according to the <italic toggle="yes">C</italic>
<sub>score</sub> values, which employ five molecular descriptors&#x0e5f8;three
related to the shape and two related to the polarity&#x0e5f8;to describe
the similarity between API and coformers (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>). A low <italic toggle="yes">C</italic>
<sub>score</sub> would indicate
that the molecules have similar shapes, and it will be easier to find
a close packing of the API and coformer in the same multicomponent
crystal. In addition, different conformations of the API and coformers
are included in the model because they can be adopted in the cocrystal.
A multicomponent score is calculated for every pair of API conformation&#x02013;coformer
conformation; then the final score is averaged over the total number
of pairs (usually 10 API conformations). The MC method was suggested
to work better when dealing with APIs where hydrogen bonding is expected
to be weaker, such as for artemisinin.<xref rid="ref47" ref-type="bibr"/> However, the case of CILP looks different; the molecule possesses
hydrogen bond donor and acceptor groups, and strong interaction might
be established, but differently from COSMOquick, the MC analysis might
be able to account for adverse packing with the coformer, which prevents
the formation of synthons in the solid state.</p><fig position="float" id="fig8" fig-type="figure"><label>8</label><caption><p>(a) Schematic representation
of the MC approach used to calculate
the complementarity score (<italic toggle="yes">C</italic>
<sub>score</sub>) of
CILP and coformers.<xref rid="ref14" ref-type="bibr"/> Molecular descriptors
representing the shape and polarity of the molecules are employed
in the calculation. Cut-off values were determined by F&#x000e1;bi&#x000e1;n
based on a statistical analysis performed on cocrystals contained
in the CSD.<named-content content-type="bibref-group">
<xref rid="ref13" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/>
</named-content> (b) Schematic representation
of the passing rule used in the default settings of the MC cocrystal
screening available in Mercury.</p></caption><graphic xlink:href="cg5c00184_0008" id="gr8" position="float"/></fig><p>An alternative screening approach performed with
the MC method
can be conducted by using the default settings provided in Mercury
(<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>). In this
case, the ranking with complementarity scores is substituted by a
strict discrimination of coformers that form and do not form cocrystals.
Cocrystal formation is predicted if, and only if, the difference of
API and coformer descriptors is within the cutoff value for all five
descriptors. The coformers tested with cilnidipine failed this test
with every API conformation, resulting in a &#x0201c;FAIL&#x0201d; classification
for all coformers (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">Table S3</ext-link>). Therefore,
the MC analysis conducted with Mercury default settings missed the
identification of the cocrystal of CILP with TSA, unlike the <italic toggle="yes">C</italic>
<sub>score</sub> screening. Researchers at the CCDC have
recently performed a validation exercise on the MC approach with the
default Mercury settings using a larger data set of cocrystals (2500
cocrystals employed) consisting of both positive and negative observations.<xref rid="ref48" ref-type="bibr"/> The validation showed that MC has variable accuracy
with small drug molecules and suggested the use of the computational
methods only on compounds with similar features to the ones contained
in F&#x000e1;bi&#x000e1;n&#x02019;s data set (small, neutral molecules
with MW &#x0003c; 300 Da).</p><p>The good prediction performance obtained
with CILP (MW = 492.5
Da) and posaconazole (Da = 700.8 Da)<xref rid="ref22" ref-type="bibr"/> contrasts
with these findings and suggests that ranking coformers using a screening
function (<italic toggle="yes">C</italic>
<sub>score</sub>) is more effective for
identifying new cocrystals than relying on a strict cutoff value discrimination
(MC with default settings). Indeed, the purpose of the computational
approach is to reduce the number of cocrystallization experiments
by prioritizing coformers at the top of the ranking list, without
needing to define a cutoff value to accurately predict every coformer
tested. Such an approach may be beneficial in the pharmaceutical industry,
where discovered molecules are becoming larger and larger, and it
is sufficient to increase the efficiency of experimental cocrystal
formation by focusing on the top-ranked coformers.</p><p>Many prospective
cocrystal screenings in the literature have tested
the MC method with the default settings method, but only a few have
calculated the complementarity score. Testing the applicability of
the complementarity score on a larger number of cocrystal systems
could further confirm the prediction performance of the method.</p></sec></sec></sec><sec id="sec4"><title>Conclusions</title><p>A new cocrystal of cilnidipine (CILP) with <italic toggle="yes">p</italic>-toluenesulfonamide
(TSA) characterized by a 1:1 stoichiometry of the components was discovered
in this study. The CILP-TSA cocrystal was identified both by manual
and semiautomatic experimental high-throughput screening approaches
from a subset of 52 coformers tested, allowing for a rapid and successful
test of several coformer candidates. In addition, the computational
tool Molecular Complementarity (MC) demonstrated good prediction performance
for the CILP cocrystal by ranking TSA as the third favorite candidate
in the list of 52 coformers, based on the complementarity score. The
MC tool proved to be valuable in the preselection of promising coformers
and in the potential reduction of experimental trials. Prediction
outcomes suggest that crystal packing contributions for cocrystal
formation need to be considered when dealing with large and flexible
APIs.</p><p>Characterization of the CILP-TSA cocrystal revealed sustained
supersaturation
over 8 h in dissolution studies conducted in blank FaSSIF and FaSSIF
pH 6.5. These results suggest that the cocrystal can achieve higher
exposure and favor drug absorption compared to crystalline CILP. The
combination of computational methods and high-throughput experimental
screening can allow for faster discovery of cocrystals of newly developed
chemical entities in the pharmaceutical industry.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data"><media xlink:href="cg5c00184_si_001.pdf"/></supplementary-material></sec></body><back><ack id="ack1"><p>This project has received funding from the European
Union&#x02019;s Horizon 2020 research and innovation program under
the Marie Sk&#x00142;odowska-Curie grant agreement No. 955756. The authors
thank Jennifer Robin for helping with the liquid handling system,
Dr. Katharina Reichenbaecher for help with the PXRD measurement in
HTS-2, Dr. Giuseppe Lapadula for fruitful discussions, and the teams
from the Solvias powder X-ray diffraction and thermal analysis laboratories
for their support. The authors thank Tina Christiansen for her support
in the laboratory at SDU.</p></ack><notes id="notes1" notes-type="si"><p>The Supporting Information
is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.cgd.5c00184?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.cgd.5c00184</ext-link>.<list list-type="simple" id="silist"><list-item><p>List of coformers employed
in the cocrystal screening;
ranking of coformers based on COSMOquick and MC methods and comparison
with HTS results; HTS experimental details; solution <sup>1</sup>H
NMR spectra and thermogravimetry for the CILP starting material and
the new cocrystal obtained; enthalpy of fusion of API, coformer, and
cocrystal; and percentage of dissolved cocrystals (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5c00184/suppl_file/cg5c00184_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations</title><def-item><term>API</term><def><p>active
pharmaceutical ingredient</p></def></def-item><def-item><term>BCS</term><def><p>Biopharmaceutics
Classification System</p></def></def-item><def-item><term>CBZ</term><def><p>carbamazepine</p></def></def-item><def-item><term>CILP</term><def><p>cilnidipine</p></def></def-item><def-item><term>CCDC</term><def><p>Cambridge Crystallographic Data Center</p></def></def-item><def-item><term>COSMO-RS</term><def><p>COnductor-like Screening MOdel for Real
Solvents</p></def></def-item><def-item><term>CSD</term><def><p>Cambridge
Structural Database</p></def></def-item><def-item><term>CSP</term><def><p>crystal structure prediction</p></def></def-item><def-item><term>DFT</term><def><p>density functional theory</p></def></def-item><def-item><term>DSC</term><def><p>differential scanning calorimetry</p></def></def-item><def-item><term>FaSSIF</term><def><p>fasted state
simulated intestinal fluid</p></def></def-item><def-item><term>FNO</term><def><p>fraction of nitrogen and oxygen atoms</p></def></def-item><def-item><term>
<sup>1</sup>H NMR</term><def><p>proton NMR</p></def></def-item><def-item><term>HTS</term><def><p>high-throughput screening</p></def></def-item><def-item><term>LAG</term><def><p>liquid-assisted
grinding</p></def></def-item><def-item><term>MC</term><def><p>molecular
complementarity</p></def></def-item><def-item><term>PS-SMPT</term><def><p>particle surface-solution-mediated phase transformation</p></def></def-item><def-item><term>PXRD</term><def><p>powder X-ray diffraction</p></def></def-item><def-item><term>RC</term><def><p>reaction crystallization</p></def></def-item><def-item><term>TSA</term><def><p>
<italic toggle="yes">p</italic>-toluenesulfonamide</p></def></def-item><def-item><term>UHPLC-UV</term><def><p>ultra-high-performance liquid chromatography coupled with
UV detection.</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name><surname>Amidon</surname><given-names>G. L.</given-names></name><name><surname>Lennern&#x000e4;s</surname><given-names>H.</given-names></name><name><surname>Shah</surname><given-names>V. P.</given-names></name><name><surname>Crison</surname><given-names>J. R.</given-names></name><article-title>A theoretical basis
for a biopharmaceutic drug classification: the correlation of in vitro
drug product dissolution and in vivo bioavailability</article-title><source>Pharm. Res.</source><year>1995</year><volume>12</volume><issue>3</issue><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1023/A:1016212804288</pub-id><pub-id pub-id-type="pmid">7617530</pub-id>
</element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name><surname>Williams</surname><given-names>H. D.</given-names></name><name><surname>Trevaskis</surname><given-names>N. L.</given-names></name><name><surname>Charman</surname><given-names>S. A.</given-names></name><name><surname>Shanker</surname><given-names>R. M.</given-names></name><name><surname>Charman</surname><given-names>W. N.</given-names></name><name><surname>Pouton</surname><given-names>C. W.</given-names></name><name><surname>Porter</surname><given-names>C. J.</given-names></name><article-title>Strategies to address low drug solubility
in discovery and development</article-title><source>Pharmacol. Rev.</source><year>2013</year><volume>65</volume><issue>1</issue><fpage>315</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1124/pr.112.005660</pub-id><pub-id pub-id-type="pmid">23383426</pub-id>
</element-citation></ref><ref id="ref3"><mixed-citation publication-type="book" id="cit3">
<person-group person-group-type="allauthors">
<string-name>
<surname>Bond</surname>, <given-names>A. D.</given-names>
</string-name>
</person-group>.
In <source>Fundamental Aspects
of Salts and Co-crystals. In Pharmaceutical Salts and Co-crystals</source>; <person-group person-group-type="editor">
<string-name>
<surname>Wouters</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Qu&#x000e9;r&#x000e9;</surname>, <given-names>L.</given-names>
</string-name>
</person-group>, Eds.; <publisher-name>The Royal Society of Chemistry</publisher-name>, <year>2011</year>; pp <fpage>9</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1039/9781849733502-00009</pub-id>.</mixed-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name><surname>Kuminek</surname><given-names>G.</given-names></name><name><surname>Rodr&#x000ed;guez-Hornedo</surname><given-names>N.</given-names></name><name><surname>Siedler</surname><given-names>S.</given-names></name><name><surname>Rocha</surname><given-names>H. V. A.</given-names></name><name><surname>Cuffini</surname><given-names>S. L.</given-names></name><name><surname>Cardoso</surname><given-names>S. G.</given-names></name><article-title>How cocrystals of
weakly basic drugs
and acidic coformers might modulate solubility and stability</article-title><source>Chem. Commun.</source><year>2016</year><volume>52</volume><issue>34</issue><fpage>5832</fpage><lpage>5835</lpage><pub-id pub-id-type="doi">10.1039/C6CC00898D</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Kuminek</surname><given-names>G.</given-names></name><name><surname>Roy</surname><given-names>L.</given-names></name><name><surname>Cavanagh</surname><given-names>K. L.</given-names></name><name><surname>Yin</surname><given-names>Q.</given-names></name><name><surname>Rodr&#x000ed;guez-Hornedo</surname><given-names>N.</given-names></name><article-title>Cocrystal Solubility Advantage Diagrams
as a Means to Control Dissolution, Supersaturation, and Precipitation</article-title><source>Mol. Pharmaceutics</source><year>2019</year><volume>16</volume><issue>9</issue><fpage>3887</fpage><lpage>3895</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00501</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name><surname>Newman</surname><given-names>L. M.</given-names></name><name><surname>Kavanagh</surname><given-names>O. N.</given-names></name><name><surname>Machado</surname><given-names>T. C.</given-names></name><article-title>DSPindex
guides dose selection to
extend drug supersaturation lifetime during cocrystal dissolution</article-title><source>Int. J. Pharm.</source><year>2025</year><volume>671</volume><fpage>125298</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2025.125298</pub-id><pub-id pub-id-type="pmid">39892676</pub-id>
</element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name><surname>Rodr&#x000ed;guez-Hornedo</surname><given-names>N.</given-names></name><name><surname>Nehm</surname><given-names>S. J.</given-names></name><name><surname>Seefeldt</surname><given-names>K. F.</given-names></name><name><surname>Pag&#x000e1;n-Torres</surname><given-names>Y.</given-names></name><name><surname>Falkiewicz</surname><given-names>C. J.</given-names></name><article-title>Reaction
Crystallization of Pharmaceutical Molecular
Complexes</article-title><source>Mol. Pharmaceutics</source><year>2006</year><volume>3</volume><issue>3</issue><fpage>362</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1021/mp050099m</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name><surname>Fri&#x00161;&#x0010d;i&#x00107;</surname><given-names>T.</given-names></name><name><surname>Childs</surname><given-names>S. L.</given-names></name><name><surname>Rizvi</surname><given-names>S. A. A.</given-names></name><name><surname>Jones</surname><given-names>W.</given-names></name><article-title>The role of solvent
in mechanochemical and sonochemical cocrystal formation: a solubility-based
approach for predicting cocrystallisation outcome</article-title><source>CrystEngComm</source><year>2009</year><volume>11</volume><issue>3</issue><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1039/B815174A</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name><surname>ter
Horst</surname><given-names>J. H.</given-names></name><name><surname>Deij</surname><given-names>M. A.</given-names></name><name><surname>Cains</surname><given-names>P. W.</given-names></name><article-title>Discovering New
Co-Crystals</article-title><source>Cryst. Growth Des.</source><year>2009</year><volume>9</volume><issue>3</issue><fpage>1531</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.1021/cg801200h</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name><surname>Roshni</surname><given-names>J.</given-names></name><name><surname>Karthick</surname><given-names>T.</given-names></name><article-title>A Comprehensive Review
on Theoretical Screening Methods
for Pharmaceutical Cocrystals</article-title><source>J. Mol. Struct.</source><year>2025</year><volume>1321</volume><fpage>139868</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2024.139868</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name><surname>Sun</surname><given-names>G.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>B.</given-names></name><name><surname>Chang</surname><given-names>C.</given-names></name><name><surname>Abramov</surname><given-names>Y. A.</given-names></name><article-title>Virtual
Coformer Screening by Crystal Structure Predictions:
Crucial Role of Crystallinity in Pharmaceutical Cocrystallization</article-title><source>J. Phys. Chem. Lett.</source><year>2020</year><volume>11</volume><issue>20</issue><fpage>8832</fpage><lpage>8838</lpage><pub-id pub-id-type="doi">10.1021/acs.jpclett.0c02371</pub-id><pub-id pub-id-type="pmid">32969658</pub-id>
</element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name><surname>Abramov</surname><given-names>Y. A.</given-names></name><name><surname>Iuzzolino</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>York</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>C.-H.</given-names></name><name><surname>Shultz</surname><given-names>C. S.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Chang</surname><given-names>C.</given-names></name><name><surname>Shi</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Greenwell</surname><given-names>C.</given-names></name><name><surname>Sekharan</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>A. Y.</given-names></name><article-title>Cocrystal
Synthesis through Crystal Structure Prediction</article-title><source>Mol. Pharmaceutics</source><year>2023</year><volume>20</volume><issue>7</issue><fpage>3380</fpage><lpage>3392</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c01098</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name><surname>F&#x000e1;bi&#x000e1;n</surname><given-names>L.</given-names></name><article-title>Cambridge
Structural Database Analysis of Molecular Complementarity in Cocrystals</article-title><source>Cryst. Growth Des.</source><year>2009</year><volume>9</volume><issue>3</issue><fpage>1436</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1021/cg800861m</pub-id></element-citation></ref><ref id="ref14"><mixed-citation publication-type="book" id="cit14">
<person-group person-group-type="allauthors">
<string-name>
<surname>F&#x000e1;bi&#x000e1;n</surname>, <given-names>L.</given-names>
</string-name>; <string-name>
<surname>Fri&#x00161;&#x0010d;i&#x00107;</surname>, <given-names>T.</given-names>
</string-name>
</person-group>. In <source>Shape
and Polarity in Co-crystal Formation: Database Analysis and Experimental
Validation. In Pharmaceutical Salts and Co-crystals</source>; <person-group person-group-type="editor">
<string-name>
<surname>Wouters</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Qu&#x000e9;r&#x000e9;</surname>, <given-names>L.</given-names>
</string-name>
</person-group>, Eds.; <publisher-name>The Royal Society of Chemistry</publisher-name>, <year>2011</year>; pp <fpage>89</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="doi">10.1039/9781849733502-00089</pub-id>.</mixed-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name><surname>Loschen</surname><given-names>C.</given-names></name><name><surname>Klamt</surname><given-names>A.</given-names></name><article-title>COSMOquick: A Novel Interface for
Fast &#x003c3;-Profile Composition
and Its Application to COSMO-RS Solvent Screening Using Multiple Reference
Solvents</article-title><source>Ind. Eng. Chem. Res.</source><year>2012</year><volume>51</volume><issue>43</issue><fpage>14303</fpage><lpage>14308</lpage><pub-id pub-id-type="doi">10.1021/ie3023675</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name><surname>Loschen</surname><given-names>C.</given-names></name><name><surname>Klamt</surname><given-names>A.</given-names></name><article-title>Solubility prediction,
solvate and cocrystal screening as tools for
rational crystal engineering</article-title><source>J. Pharm. Pharmacol.</source><year>2015</year><volume>67</volume><issue>6</issue><fpage>803</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1111/jphp.12376</pub-id><pub-id pub-id-type="pmid">25851032</pub-id>
</element-citation></ref><ref id="ref17"><mixed-citation publication-type="book" id="cit17">
<person-group person-group-type="allauthors">
<string-name>
<surname>Loschen</surname>, <given-names>C.</given-names>
</string-name>; <string-name>
<surname>Klamt</surname>, <given-names>A.</given-names>
</string-name>
</person-group>
<article-title>New Developments in Prediction
of Solid-State Solubility and Cocrystallization Using COSMO-RS Theory</article-title>. In <source>Computational Pharmaceutical Solid State Chemistry</source>; <publisher-name>Wiley</publisher-name>, <year>2016</year>; pp <fpage>211</fpage>&#x02013;<lpage>233</lpage>.<pub-id pub-id-type="doi">10.1002/9781118700686.ch9</pub-id>.</mixed-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name><surname>Klamt</surname><given-names>A.</given-names></name><article-title>The COSMO
and COSMO-RS solvation models</article-title><source>Wiley. Comput.
Mol. Sci.</source><year>2018</year><volume>8</volume><issue>1</issue><elocation-id>e1338</elocation-id><pub-id pub-id-type="doi">10.1002/wcms.1338</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name><surname>Klamt</surname><given-names>A.</given-names></name><name><surname>Eckert</surname><given-names>F.</given-names></name><article-title>COSMO-RS: a novel and
efficient method for the a priori
prediction of thermophysical data of liquids</article-title><source>Fluid Phase Equilib.</source><year>2000</year><volume>172</volume><issue>1</issue><fpage>43</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0378-3812(00)00357-5</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Hou</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>Z.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><article-title>Multicomponent
Crystal Screening and Performance Testing of Sunitinib: A Combined
Virtual and Experimental Study</article-title><source>Cryst. Growth
Des.</source><year>2024</year><volume>24</volume><issue>19</issue><fpage>8112</fpage><lpage>8134</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.4c01059</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name><surname>Cappuccino</surname><given-names>C.</given-names></name><name><surname>Cusack</surname><given-names>D.</given-names></name><name><surname>Flanagan</surname><given-names>J.</given-names></name><name><surname>Harrison</surname><given-names>C.</given-names></name><name><surname>Holohan</surname><given-names>C.</given-names></name><name><surname>Lestari</surname><given-names>M.</given-names></name><name><surname>Walsh</surname><given-names>G.</given-names></name><name><surname>Lusi</surname><given-names>M.</given-names></name><article-title>How Many Cocrystals
Are We Missing? Assessing Two Crystal Engineering Approaches to Pharmaceutical
Cocrystal Screening</article-title><source>Cryst. Growth Des.</source><year>2022</year><volume>22</volume><issue>2</issue><fpage>1390</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.1c01342</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name><surname>Guidetti</surname><given-names>M.</given-names></name><name><surname>Hilfiker</surname><given-names>R.</given-names></name><name><surname>Kuentz</surname><given-names>M.</given-names></name><name><surname>Bauer-Brandl</surname><given-names>A.</given-names></name><name><surname>Blatter</surname><given-names>F.</given-names></name><article-title>Exploring the Cocrystal Landscape
of Posaconazole by
Combining High-Throughput Screening Experimentation with Computational
Chemistry</article-title><source>Cryst. Growth Des.</source><year>2023</year><volume>23</volume><issue>2</issue><fpage>842</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.2c01072</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Mai</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Di</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><article-title>A wet-milling
method for the preparation of cilnidipine nanosuspension
with enhanced dissolution and oral bioavailability</article-title><source>J. Drug Delivery Sci. Technol.</source><year>2020</year><volume>55</volume><fpage>101371</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101371</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name><surname>Indulkar</surname><given-names>A. S.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Raina</surname><given-names>S. A.</given-names></name><name><surname>Zhang</surname><given-names>G. G. Z.</given-names></name><name><surname>Taylor</surname><given-names>L. S.</given-names></name><article-title>Crystallization
from Supersaturated Solutions: Role of Lecithin and Composite Simulated
Intestinal Fluid</article-title><source>Pharm. Res.</source><year>2018</year><volume>35</volume><issue>8</issue><fpage>158</fpage><pub-id pub-id-type="doi">10.1007/s11095-018-2441-2</pub-id><pub-id pub-id-type="pmid">29916053</pub-id>
</element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name><surname>Lodagekar</surname><given-names>A.</given-names></name><name><surname>Chavan</surname><given-names>R. B.</given-names></name><name><surname>Chella</surname><given-names>N.</given-names></name><name><surname>Shastri</surname><given-names>N. R.</given-names></name><article-title>Role of
Valsartan
as an Antiplasticizer in Development of Therapeutically Viable Drug&#x02013;Drug
Coamorphous System</article-title><source>Cryst. Growth Des.</source><year>2018</year><volume>18</volume><issue>4</issue><fpage>1944</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.8b00081</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name><surname>Bapat</surname><given-names>P.</given-names></name><name><surname>Paul</surname><given-names>S.</given-names></name><name><surname>Tseng</surname><given-names>Y.-C.</given-names></name><name><surname>Taylor</surname><given-names>L. S.</given-names></name><article-title>Interplay of Drug&#x02013;Polymer
Interactions and Release Performance for HPMCAS-Based Amorphous Solid
Dispersions</article-title><source>Mol. Pharmaceutics</source><year>2024</year><volume>21</volume><issue>3</issue><fpage>1466</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c01106</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name><surname>Saboo</surname><given-names>S.</given-names></name><name><surname>Mugheirbi</surname><given-names>N. A.</given-names></name><name><surname>Zemlyanov</surname><given-names>D. Y.</given-names></name><name><surname>Kestur</surname><given-names>U. S.</given-names></name><name><surname>Taylor</surname><given-names>L. S.</given-names></name><article-title>Congruent
release of drug and polymer: A &#x0201c;sweet spot&#x0201d; in the dissolution
of amorphous solid dispersions</article-title><source>J. Controlled
Release</source><year>2019</year><volume>298</volume><fpage>68</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.01.039</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name><surname>Klamt</surname><given-names>A.</given-names></name><article-title>The COSMO
and COSMO-RS solvation models</article-title><source>Wiley. Comput.
Mol. Sci.</source><year>2011</year><volume>1</volume><issue>5</issue><fpage>699</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1002/wcms.56</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name><surname>Perdew</surname><given-names>J. P.</given-names></name><article-title>Density-functional
approximation for the correlation energy of the inhomogeneous electron
gas</article-title><source>Phys. Rev. B</source><year>1986</year><volume>33</volume><issue>12</issue><fpage>8822</fpage><lpage>8824</lpage><pub-id pub-id-type="doi">10.1103/PhysRevB.33.8822</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Huber</surname><given-names>C.</given-names></name><name><surname>Ahlrichs</surname><given-names>R.</given-names></name><article-title>Fully optimized contracted
Gaussian
basis sets of triple zeta valence quality for atoms Li to Kr</article-title><source>J. Chem. Phys.</source><year>1994</year><volume>100</volume><issue>8</issue><fpage>5829</fpage><lpage>5835</lpage><pub-id pub-id-type="doi">10.1063/1.467146</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name><surname>Becke</surname><given-names>A. D.</given-names></name><article-title>Density-functional
exchange-energy approximation with correct asymptotic behavior</article-title><source>Phys. Rev. A</source><year>1988</year><volume>38</volume><issue>6</issue><fpage>3098</fpage><lpage>3100</lpage><pub-id pub-id-type="doi">10.1103/PhysRevA.38.3098</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name><surname>Metherall</surname><given-names>J. P.</given-names></name><name><surname>Corner</surname><given-names>P. A.</given-names></name><name><surname>McCabe</surname><given-names>J. F.</given-names></name><name><surname>Hall</surname><given-names>M. J.</given-names></name><name><surname>Probert</surname><given-names>M. R.</given-names></name><article-title>High-throughput
nanoscale crystallization of dihydropyridine active pharmaceutical
ingredients</article-title><source>Acta Crystallogr., Sect. B</source><year>2024</year><volume>80</volume><issue>1</issue><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1107/S2052520623010053</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ai</surname><given-names>J.</given-names></name><article-title>Study of the
Polymorphs and Dissolution of Cilnidipine
Tablets</article-title><source>Chin. J. Mod. Appl. Pharm.</source><year>2016</year><volume>33</volume><issue>12</issue><fpage>1539</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.13748/j.cnki.issn1007-7693.2016.12.012</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Shan</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><article-title>Study of the structures
of photodegradation impurities and pathways
of photodegradation of cilnidipine by liquid chromatography/Q-Orbitrap
mass spectrometry</article-title><source>Rapid Commun. Mass Spectrom.</source><year>2016</year><volume>30</volume><issue>15</issue><fpage>1771</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.1002/rcm.7657</pub-id><pub-id pub-id-type="pmid">27426453</pub-id>
</element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name><surname>Rager</surname><given-names>T.</given-names></name><name><surname>Hilfiker</surname><given-names>R.</given-names></name><article-title>Stability Domains of
Multi-Component Crystals in Ternary
Phase Diagrams</article-title><source>Z. fur Phys. Chem.</source><year>2009</year><volume>223</volume><issue>7</issue><fpage>793</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1524/zpch.2009.5454</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name><surname>Raina</surname><given-names>S. A.</given-names></name><name><surname>Van Eerdenbrugh</surname><given-names>B.</given-names></name><name><surname>Alonzo</surname><given-names>D. E.</given-names></name><name><surname>Mo</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>G. G. Z.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Taylor</surname><given-names>L. S.</given-names></name><article-title>Trends in the Precipitation and Crystallization
Behavior of Supersaturated Aqueous Solutions of Poorly Water-Soluble
Drugs Assessed Using Synchrotron Radiation</article-title><source>J. Pharm. Sci.</source><year>2015</year><volume>104</volume><issue>6</issue><fpage>1981</fpage><lpage>1992</lpage><pub-id pub-id-type="doi">10.1002/jps.24423</pub-id><pub-id pub-id-type="pmid">25808078</pub-id>
</element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name><surname>Baird</surname><given-names>J. A.</given-names></name><name><surname>Van Eerdenbrugh</surname><given-names>B.</given-names></name><name><surname>Taylor</surname><given-names>L. S.</given-names></name><article-title>A Classification System to Assess
the Crystallization Tendency of Organic Molecules from Undercooled
Melts</article-title><source>J. Pharm. Sci.</source><year>2010</year><volume>99</volume><issue>9</issue><fpage>3787</fpage><lpage>3806</lpage><pub-id pub-id-type="doi">10.1002/jps.22197</pub-id><pub-id pub-id-type="pmid">20623696</pub-id>
</element-citation></ref><ref id="ref38"><mixed-citation publication-type="weblink" id="cit38">
<person-group person-group-type="allauthors">
<collab>CAS</collab>
</person-group>. <article-title>
<italic toggle="yes">p</italic>-Toluenesulfonamide - compound
properties</article-title>. <uri xlink:href="https://commonchemistry.cas.org/detail?cas_rn=70-55-3">https://commonchemistry.cas.org/detail?cas_rn=70-55-3</uri> (accessed 20 Oct, <year>2024</year>).</mixed-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name><surname>Gnutzmann</surname><given-names>T.</given-names></name><name><surname>Kahlau</surname><given-names>R.</given-names></name><name><surname>Scheifler</surname><given-names>S.</given-names></name><name><surname>Friedrichs</surname><given-names>F.</given-names></name><name><surname>R&#x000f6;ssler</surname><given-names>E. A.</given-names></name><name><surname>Rademann</surname><given-names>K.</given-names></name><name><surname>Emmerling</surname><given-names>F.</given-names></name><article-title>Crystal growth
rates and molecular dynamics of nifedipine</article-title><source>CrystEngComm</source><year>2013</year><volume>15</volume><issue>20</issue><fpage>4062</fpage><lpage>4069</lpage><pub-id pub-id-type="doi">10.1039/c2ce26911b</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name><surname>Chan</surname><given-names>K. L.
A.</given-names></name><name><surname>Fleming</surname><given-names>O. S.</given-names></name><name><surname>Kazarian</surname><given-names>S. G.</given-names></name><name><surname>Vassou</surname><given-names>D.</given-names></name><name><surname>Chryssikos</surname><given-names>G. D.</given-names></name><name><surname>Gionis</surname><given-names>V.</given-names></name><article-title>Polymorphism and devitrification of nifedipine under
controlled humidity: a combined FT-Raman, IR and Raman microscopic
investigation</article-title><source>J. Raman Spectrosc.</source><year>2004</year><volume>35</volume><issue>5</issue><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1002/jrs.1139</pub-id></element-citation></ref><ref id="ref41"><mixed-citation publication-type="book" id="cit41">
<person-group person-group-type="allauthors">
<string-name>
<surname>Socrates</surname>, <given-names>G.</given-names>
</string-name>
</person-group>
<source>Infrared and Raman Characteristic
Group Frequencies: Tables and Charts</source>; <publisher-name>Wiley</publisher-name>: <publisher-loc>Chichester</publisher-loc>, <year>2004</year>. ISBN:
978-0-470-09307-8.</mixed-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name><surname>Daniel</surname><given-names>A.
B.</given-names></name><name><surname>Aruldhas</surname><given-names>D.</given-names></name><name><surname>Joe</surname><given-names>I. H.</given-names></name><name><surname>Arun Sasi</surname><given-names>B. S.</given-names></name><article-title>Experimental
and computational approach on p-toluenesulfonamide and its derivatives</article-title><source>J. Mol. Struct.</source><year>2020</year><volume>1218</volume><fpage>128503</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2020.128503</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name><surname>Mendis</surname><given-names>N. P.</given-names></name><name><surname>Lakerveld</surname><given-names>R.</given-names></name><article-title>An In Vitro
Model for Cocrystal Dissolution with Simultaneous
Surface and Bulk Precipitation</article-title><source>Mol. Pharmaceutics</source><year>2023</year><volume>20</volume><issue>11</issue><fpage>5486</fpage><lpage>5499</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00334</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name><surname>Omori</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>T.</given-names></name><name><surname>Uekusa</surname><given-names>T.</given-names></name><name><surname>Oki</surname><given-names>J.</given-names></name><name><surname>Inoue</surname><given-names>D.</given-names></name><name><surname>Sugano</surname><given-names>K.</given-names></name><article-title>Effects of Coformer and Polymer on
Particle Surface
Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media</article-title><source>Mol. Pharmaceutics</source><year>2020</year><volume>17</volume><issue>10</issue><fpage>3825</fpage><lpage>3836</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00587</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name><surname>Kirubakaran</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Rosbottom</surname><given-names>I.</given-names></name><name><surname>Cross</surname><given-names>R. B. M.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><article-title>Understanding
the Effects of a Polymer on the Surface Dissolution of Pharmaceutical
Cocrystals Using Combined Experimental and Molecular Dynamics Simulation
Approaches</article-title><source>Mol. Pharmaceutics</source><year>2020</year><volume>17</volume><issue>2</issue><fpage>517</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00955</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name><surname>Lipert</surname><given-names>M. P.</given-names></name><name><surname>Rodr&#x000ed;guez-Hornedo</surname><given-names>N.</given-names></name><article-title>Cocrystal
Transition Points: Role
of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents</article-title><source>Mol. Pharmaceutics</source><year>2015</year><volume>12</volume><issue>10</issue><fpage>3535</fpage><lpage>3546</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00111</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name><surname>Wood</surname><given-names>P. A.</given-names></name><name><surname>Feeder</surname><given-names>N.</given-names></name><name><surname>Furlow</surname><given-names>M.</given-names></name><name><surname>Galek</surname><given-names>P. T. A.</given-names></name><name><surname>Groom</surname><given-names>C. R.</given-names></name><name><surname>Pidcock</surname><given-names>E.</given-names></name><article-title>Knowledge-based approaches
to co-crystal design</article-title><source>CrystEngComm</source><year>2014</year><volume>16</volume><issue>26</issue><fpage>5839</fpage><lpage>5848</lpage><pub-id pub-id-type="doi">10.1039/c4ce00316k</pub-id></element-citation></ref><ref id="ref48"><mixed-citation publication-type="weblink" id="cit48">
<person-group person-group-type="allauthors">
<collab>CCDC</collab>
</person-group>. <article-title>CSD Molecular Complementarity Tool
Domain of Applicability</article-title>. <year>2022</year>. <uri xlink:href="https://www.ccdc.cam.ac.uk/discover/blog/csd-molecular-complementarity-domain-applicability/">https://www.ccdc.cam.ac.uk/discover/blog/csd-molecular-complementarity-domain-applicability/</uri>(accessed 31 Sep, 2024).</mixed-citation></ref></ref-list></back></article><!--Stylesheet Name and Version:openaccess.xsl v2.1
Date and Time: 2025-05-23T06:25:26.375-04:00
XML Format:jats-->